Tag

Schedule Iii

All articles tagged with #schedule iii

policy20 days ago•6 min saved

DEA Expands Federal Registration for Medical Cannabis Firms Ahead of Schedule III Move

DEA says it will roll out new registration forms for Medical Marijuana Manufacturer, Bulk Manufacturer, Analytical Lab, and Distributor to align with the DOJ’s phased move of marijuana from Schedule I to Schedule III. The current 60-day dispensary registration window ends June 26, and the new forms will be posted in coming weeks on the DEA Diversion Registration page. The applications will require details on licenses, security measures, ownership, suppliers, and access to controlled substances, and carry a nonrefundable $794 fee (PayPal now; other payment options to be added). The update is part of broader rescheduling actions, which include an expedited hearing process starting June 29; IRS guidance on taxes and ATF form updates are also anticipated as federal policy shifts on cannabis.

via Marijuana Moment|

#dea #marijuana-policy #medical-cannabis

politics1 month ago•4 min saved

DEA Opens Registration Portal as Medical Cannabis Gains Federal Protections

The DEA will begin accepting applications this week for federal protections under the cannabis rescheduling plan, launching a Medical Marijuana Dispensary Registration Portal as marijuana moves from Schedule I to Schedule III in phases. Applicants must provide extensive details on licensing, security, suppliers, and personnel, and pay a $794 fee (currently via PayPal). The process accompanies an expedited administrative hearing to consider broader rescheduling, with forthcoming tax guidance from Treasury/IRS and White House framing the move as broadly popular and beneficial for patients and farmers.

via Marijuana Moment|

#cannabis #dea #medical-marijuana

politics1 month ago•12 min saved

Tax Guidance Ahead as Marijuana Is Reclassified to Schedule III

Federal officials say they will issue new tax guidance for the marijuana industry after the Trump administration reclassified cannabis so state-licensed medical cannabis moves to Schedule III while recreational cannabis remains Schedule I for now; the change is not a federal legalization but could allow medical cannabis businesses to deductions and credits previously blocked by IRS 280E. The guidance is expected to explain how expenses should be allocated for entities with both medical and recreational activities, with possible retrospective relief in some years, and comes as a summer hearing process considers broader rescheduling. Separately, the DOJ said rescheduling doesn’t change gun-rights considerations in a pending case, and Trump praised the medical benefits of cannabis.

via Marijuana Moment|

#280e #marijuana #politics

politics1 month ago•3 min saved

Cannabis moved to Schedule III, easing research and banking while federal legalization remains off the table

The Trump administration moved cannabis from Schedule I to Schedule III under the DEA, easing federal research barriers and allowing FDA-approved products and state-licensed items to be treated as Schedule III, while opening banking access and tax deductions for cannabis businesses. An expedited June hearing will also consider formal reclassification back to Schedule I at the federal level, signaling a broader, cautious shift in federal cannabis policy without legalizing it federally.

via CNBC|

#banking #cannabis #politics

politics1 month ago•1 min saved

US shifts cannabis to Schedule III, signaling policy rethink

The Justice Department reclassified cannabis from Schedule I to Schedule III, a historic policy shift that could boost research and access while marijuana remains illegal at the federal level. Acting Attorney General Todd Blanche ordered the reclassification, following President Trump’s directive, applying to FDA-regulated products and state-licensed medical marijuana. Once published in the Federal Register, the rule takes effect after 30 days and may face legal challenges, with a DEA hearing planned for late June.

via BBC|

#cannabis #drug-policy #federal-law

politics9 months ago•1 min saved

Trump Considers Reclassifying Marijuana at Federal Level

Trump is considering reclassifying marijuana as a Schedule III drug, which would reduce penalties, and has expressed support for marijuana legalization in Florida, though he has not committed to a decision yet. The move is controversial among his base, with some opposing it to protect public spaces.

via Politico|

#2024-elections #marijuana #politics

finance2 years ago•2 min saved

DEA's Potential Marijuana Reform Sparks Stock Surge and Political Tensions

Cannabis stocks surged after rumors of the DEA potentially rescheduling marijuana to Schedule III, prompting significant gains for industry leaders like Curaleaf Holdings, Canopy Growth, and Aurora Cannabis. If the rescheduling occurs, it could lead to lower taxes for cannabis companies and more competitive prices for consumers. The Benzinga Cannabis Capital Conference in Florida will provide a platform for industry networking and growth opportunities.

via Benzinga|

#cannabis #dea #finance

health2 years ago•3 min saved

"Potential Re-Categorization of Marijuana Restrictions by Health Officials"

The Department of Health & Human Services is recommending to the Drug Enforcement Agency to re-categorize marijuana from a Schedule I drug to a Schedule III drug, which would place it in the same group as anabolic steroids. State Senator Gregg Schmedes expresses concerns about pediatric cannabis exposure, while CEO of Smokin' Dispensaries highlights the medical benefits. The impact on New Mexico and the cannabis industry, as well as the timeline for any changes, will be discussed in a news segment tonight.

via KOAT New Mexico|

#cannabis-industry #drug-enforcement-agency #health

drug-policy2 years ago•3 min saved

"U.S. Health Officials Push for Looser Marijuana Restrictions: What You Need to Know"

The U.S. Department of Health and Human Services has requested the Drug Enforcement Agency (DEA) to consider loosening restrictions on marijuana by moving it from a Schedule I to a Schedule III drug classification. This could have significant implications for the cannabis industry, including new tax opportunities, potential for interstate commerce, expanded research, and increased investor interest. However, federal legalization and access to banking services for the industry still require further legislative action. The DEA is expected to make a decision before the 2024 presidential election.

via CNBC|

#cannabis-industry #drug-enforcement-agency #drug-policy

cannabis2 years ago•5 min saved

"Federal Health Agency Pushes for Marijuana Rescheduling, Sparks Hope for Legalization"

The Department of Health and Human Services (HHS) has recommended that cannabis be moved from Schedule I to Schedule III of the Controlled Substances Act, marking a historic acknowledgment that cannabis has been misclassified. While this recommendation does not immediately legalize marijuana or impact the cannabis industry significantly, it could lead to the elimination of the 280e tax code, which currently hinders profitability for cannabis businesses. This change may also attract new sources of capital and lending to the industry. Additionally, rescheduling could prompt the Toronto Stock Exchange and potentially other exchanges to accept U.S.-based cannabis companies. The HHS recommendation may also encourage Congress to take further action on cannabis reform. Overall, this announcement brings the United States closer to a post-prohibition reality.

via Forbes|

#280e-tax-code #cannabis #cannabis-industry

health2 years ago•5 min saved

Federal Health Agency Urges Marijuana Reclassification for Lower Risk

The Department of Health and Human Services (HHS) has recommended to the Drug Enforcement Administration (DEA) that marijuana be reclassified as a lower-risk, Schedule III controlled substance, a move that could lead to a significant shift in federal policy on cannabis. While this would not outright legalize marijuana at the federal level, it could boost the regulated marijuana industry in states where it is legal and facilitate more scientific research into the drug's effects. The recommendation aligns with President Biden's efforts to reshape marijuana policies, and if accepted by the DEA, it would mark a historic step in cannabis reform. However, advocates for full legalization argue that the recommendation doesn't go far enough and that cannabis should be treated similarly to tobacco and alcohol.

via The Washington Post|

#cannabis-industry #drug-enforcement-administration #federal-policy

drug-policy2 years ago•6 min saved

Biden administration pushes for marijuana reclassification, boosting cannabis stocks

The Biden administration's Department of Health and Human Services (HHS) has recommended that the Drug Enforcement Agency (DEA) loosen federal restrictions on marijuana by moving it from Schedule I to Schedule III under the Controlled Substances Act (CSA). This recommendation, based on a review conducted by the Food and Drug Administration (FDA), could be the biggest change in federal drug policy in decades. However, the HHS stopped short of advising complete removal of marijuana from the CSA. The DEA has the final authority to schedule or reschedule a drug, and it will now initiate its review. Rescheduling cannabis to Schedule III could have significant implications for the cannabis industry, including lower federal taxes and easier access to banking services. It could also facilitate research on cannabis and the development of cannabis-based pharmaceuticals. However, advocates argue that rescheduling alone does not address the issue of criminalization.

via POLITICO|

#biden-administration #cannabis #drug-enforcement-agency

drug-policy2 years ago•1 min saved

HHS Official Urges Reclassification of Marijuana to Lower-Risk Drug Category

The U.S. Department of Health and Human Services (HHS) has recommended that marijuana be reclassified as a Schedule III drug, according to a letter addressed to the Drug Enforcement Agency (DEA) administrator. Currently classified as a Schedule I drug, the move would ease restrictions on marijuana and align with the legalization efforts in about 40 U.S. states. The DEA confirmed receiving the letter and stated that it will initiate a review. Cannabis companies and advocates welcomed the HHS recommendation, citing the need to end the harm caused by marijuana prohibition.

via Reuters|

#dea #drug-classification #drug-policy